Boston Scientific Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.comGroups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're diving into Boston Scientific's second quarter 2026 results — and Jordan, this one's got some real drama in it.JORDAN: It really does. Before we jump in, quick disclaimer for everyone listening: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Right, so let's set the scene. Boston Scientific actually beat expectations in Q2 — organic sales grew 7%, ahead of their 5-7% guide, and adjusted EPS came in at 86 cents, up 15% year-over-year and above the high end of guidance.JORDAN: On paper, that sounds like a great quarter. But here's the twist — right after touting the beat, management turned around and cut full-year guidance. Full-year organic revenue guidance moved down to 5-6%, and full-year EPS guidance came in at $3.28 to $3.32.ALEX: And the culprit? Two of their hottest businesses over the last couple years — WATCHMAN and electrophysiology, or EP.JORDAN: Let's start with WATCHMAN, the left atrial appendage closure device. This is a fascinating case of clinical evidence essentially colliding with commercial momentum. New studies — OCEAN, CHAMPION-AF — have been published over the past several months, and they're changing how doctors think about referring patients for the procedure.ALEX: CEO Mike Mahoney was pretty candid about it. He said the U.S. market has "slowed sharply and unexpectedly." Standalone WATCHMAN procedures — meaning not done alongside another heart procedure — are actually declining in the low teens percentage-wise.JORDAN: The one bright spot is "concomitant" procedures — done at the same time as another cardiac procedure — which grew over 60%. But even that's expected to slow in the second half because of tougher comparisons.ALEX: So full-year WATCHMAN growth guidance is now flat to low single digits, with the second half actually expected to decline mid-to-high single digits. That's a big swing from where this business has been.JORDAN: Then there's EP, the electrophysiology business built around their FARAPULSE technology — that's the pulsed field ablation, or PFA, platform for treating atrial fibrillation. Management admitted they simply underestimated competitive pressure in the U.S.ALEX: Which is almost ironic, because Boston Scientific basically created this PFA market boom. Mahoney noted PFA now makes up something like 80% of the U.S. AFib ablation market — a shift that happened faster than anyone expected, and that success invited competitors in quicker than the company modeled.JORDAN: Meanwhile, international EP growth is still humming along around 20%. It's really a U.S.-specific share story, not a "the technology doesn't work" story.ALEX: Here's something I found reassuring, though. Management pointed out that roughly 75% of Boston Scientific's revenue — everything outside WATCHMAN and EP — is still expected to grow about 6% in the second half, which is right in line with their historical trend.JORDAN: Right, and there were genuinely strong pockets. Neuromodulation grew 12%. Interventional cardiology grew 15%. Interventional oncology grew 12%. This isn't a company falling apart — it's two specific franchises hitting an air pocket.ALEX: Let's talk strategy, because they also announced a restructuring program targeting about $500 million in run-rate savings by the end of 2029, with more than half of that realized by exiting 2027.JORDAN: That's a real signal — they're bracing for a tougher stretch and want to fund future growth catalysts without blowing up margins. CFO Jon Monson said savings will show up first in SG&A, then in cost of goods sold over time.ALEX: And on thThis episode includes AI-generated content.